A new series of coumarin and benzofuran derivatives were synthesized as potential non-nucleoside reverse transcriptase inhibitors (NNRTIs) by reacting, separately, 4-bromomethylcoumarins, their sulphonyl chlorides, and ethyl 3-(bromomethyl)-6-methoxy-1-benzofuran-2-carboxylate with different imidazoles and their benzo analogs. The antiviral (HIV-1, HIV-2) properties of the newly synthesized compounds were investigated in vitro and all compounds were found to be inactive, except 10 which showed inhibition of HIV-2 with EC 50 > 0.51 µg mL −1 . The in vitro cytotoxicity of 17 and 19 was assayed against a panel of tumor cell lines consisting of CD4 human T-cells.
Introduction
Several coumarins constitute an important class of naturally occurring compounds with useful pharmacological activity [1 -4] as antibacterial and antifungal agents, [5, 6] and as serine proteases inhibitors [7] . Geiparvarin (1), a naturally occurring compound bearing a coumarin residue, has been shown to possess a significant inhibitory activity against a variety of cell lines including sarcoma 180, Lewis lung carcinoma, P-388 lymphocytic leukaemia, and Walker 256 carcinosarcoma [8, 9] . In addition, some Geiparvarin analogs displayed interesting biological activity [10] ; warfarin and some bis-hydroxycoumarins have been used as oral anticoagulants [11] , β -adrenergic blocking agents [12] , and vasorelaxants [13] .
Recently, cloricromene, a coumarin derivative, was reported as a protector against collagen-induced arthritis in Lewis rats [14] , and new furanocoumarin ethers of falcarindol, named japonagelol, have been prepared as novel antiproliferative agents [15] .
On the other hand, it was reported that compounds having imidazole moieties, such as Dacarbazine ® (DTIC) [16] , and Temozolomide, the lymphoma and malignant melanoma agent, and misonidazole [17] , the inhibitor of de novo purine synthesis, clotrinazole is an imidazole analog with a high anti-HIV inhibitory activity [20] . Some compounds of nitroimidazoles are reported as potent and selective histamine H-3 receptor agonists [21, 22] , mitogen-activated protein (MAP) kinases inhibitors [23 -27] , nitric-oxide synthase inhibitors [28] and anti-inflammatory agents [29] .
Motivated by these pharmacological activities, and in continuation of our work on coumarins [30, 31] and 5-nitroimidazoles [32 -36] , we report herein on the synthesis of new coumarin derivatives and the evaluation of their anti-HIV activity.
Results and Discussion

Synthesis
Compound 4 has been selected as a starting material for the synthesis of new potentially active substituted coumarin derivatives; reaction of 4 with the 4-bromomethylcoumarins 5 and 6 in dimethylformamide (DMF) afforded the corresponding products 7 and 8 in 43 and 56 % yield, respectively (Scheme 1). Scheme 1. Synthesis of the title compounds 7 -11.
The
1 H NMR and 13 C NMR spectra of all prepared compounds are in agreement with the suggested structures. DEPT experiments were employed to differentiate secondary and quaternary from primary and tertiary carbons. Additional support of the proposed structures comes from mass spectral data; mass spectra of the prepared compounds showed the correct molecular ions, as suggested by their molecular formulas. The 1 H NMR spectra of 7 and 8 showed similar patterns; the piperazine hydrogens appeared as broad singlets at δ H = 3.32 and 3.34 ppm, respectively, while the singlets in the region δ H = 5.14 and 5.19 ppm were attributed to the methylene hydrogens of the benzyl group. The signals of coumarin protons (5-H, 6-H, 8-H) appeared as multiplets in the ranges of δ H = 7.02 -7.66 and δ H = 6.95 -7.87 ppm. The chemical shifts at δ C = 160.7 -160.9 ppm were assigned to the carbonyl carbon of the benzopyran ring (C-2). The piperazine carbons, on the other hand, appeared at δ C = 46.2 -49.3. Moreover, treatment of 9 with 5 and 6 in DMF and NaH afforded, after purification, 10 and 11 in 70 and 78 % yield, respectively (Scheme 1). The identities of compounds 10 and 11 were confirmed by their 1 H, 13 C NMR and mass spectra.
Coumarin derivatives containing benzoxazole and benzothiazole moieties were also synthesized from the reactions of 2-(piperazin-1-yl)benzo[d]oxazole (12) and 2-(piperazin-1-yl)benzo[d]thiazole (13) [34] . Compound 14 was prepared in 67 % yield from the benzoxazole derivative 12 in the presence of NaH/DMF. Treatment of 15, which was prepared from 13 and 2-chloroacetyl chloride, with potassium phthalamide in the presence of K 2 CO 3 afforded 16 in 90 % yield which was then converted to the corresponding amine 17 by treatment with hydrazine hydrate [35] . Sulfonylation of 17 with the coumarinsulfonyl chloride derivative 18 in the presence of triethylamine yielded the sulfonamide derivative 19 in 71 % yield (Scheme 2).
The piperazine protons in the 1 H NMR spectra of 14 -17 and 19 appeared as broad singlets at δ H = 3.48 -3.92 ppm. The COCH 2 protons of 15 and 16 appeared as singlets at δ H = 4.14 and 4.56 ppm. The CH 2 NH protons of 17 and 19 appeared as doublets Scheme 2. Reagents: i) chloroacetyl chloride; ii) potassium phthalamide, K 2 CO 3 ; iii) hydrazine hydrate. The new imidazole derivatives 21 and 22 were synthesized from the benzofuran derivative 20 by treatment with 4 and 9, respectively, in the presence of NaH in DMF (Scheme 3). The structures of the newly prepared compounds 21 and 22 were determined by their 1 H, 13 C NMR, and mass spectra. Compounds 7, 8, 10, 11, 19, 21 , and 22 were tested for their in vitro anti-HIV-1 (strain III B ) and HIV-2 (strain ROD) activity in human T-lymphocyte (MT-4) cells. None of the in vitro tested compounds were found to inhibit HIV-replication, at EC 50 lower than the CC 50 compared to the antiviral agents efavirenz (EFV) [36] and capravirine [37] . However, compound 10 showed an inhibition of HIV-1 with an EC 50 of 1.22 µg mL −1 and HIV-2 with an EC 50 of 0.51 µg mL −1 , while compound 11 showed an inhibition of HIV-1 with an EC 50 of 1.45 µg mL −1 and HIV-2 with an EC 50 of 1.78 µg mL −1 at non-toxic concentrations with no selectivity witnessed. Results are shown in Table 1 . 
In vitro anti-HIV assay
In vitro antitumor assay
The Microculture Tetrazolium Assay (MTT) method [38] , which is based on metabolic reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, was used for a preliminary estimation of the in vitro tumor-inhibiting activity of the benzothiazole derivatives 17 and against a panel of tumor cell lines. The results are summarized in Table 2 . Comparing the activities of 19 to 17 showed that the inclusion of the sulphonamide moiety shifted the threshold of potency from the inactive side toward activity, particularly against the CD4 + human acute T-lymphoblastic leukaemia cell line (CCRF-CEM) (IC 50 = 52 ± 9 µg mL −1 ). It is noticed that the substances with a primary ethylamine residue are inactive, e. g. 17, whereas the sulphonamide derivative 19 shows some activity. This may be due to the sulphonamide residue, which performs more intermolecular interactions. This result prompted us to modify the structure of 19 by synthesis of new benzothiazole-piperazine backbones bearing various substituted aryl sulphonamide groups.
Experimental Section
General
Melting points were measured with a B-545 Büchi melting point apparatus (Büchi Labortechnik AG, Switzerland) and are uncorrected. 1 H NMR and 13 C NMR spectra were recorded at 250 MHz ( 1 H) and at 150.91 MHz ( 13 C) with a Bruker DPX-300 spectrometer (Bruker, Germany) and are reported in ppm (δ ) relative to TMS as an internal standard and in CDCl 3 as a solvent. EIMS spectra were obtained using a Finnegan FAB MAT 8200 spectrometer (Finnigan MAT, USA) at 70 eV. Elemental analyses were acquired with the aid of a Vario Elementar apparatus (Shimadzu).
Physical data for the synthesized compounds are given in Table 3 . Synthetic routes are presented in Schemes 1 -3.
4-((4-(1-Benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)piperazin-1-yl)methyl)-7-methyl-coumarin (7)
To a solution of 4 [31] (0.32 g, 1.0 mmol) and NaH (1.0 mmol) in DMF (15 mL) was added a solution of 5 [39] (0.25 g, 1.0 mmol) in DMF (5 mL), and the mixture was stirred at 23 • C for 48 h. The solvent was evaporated and the residue was partitioned between CH 2 Cl 2 (40 mL) and water (40 mL). The organic phase was dried (Na 2 SO 4 ), filtered, and evaporated to dryness. The residue was chromatographed on silica gel plates using CH 2 Cl 2 -MeOH (9 : 1) as eluent to give 7 (0.21 g). C-3, C-4a), 53.3 (CH 2 -piperazine), 46.2, 46.4 
4-((4-(1-Benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)piperazin-1-yl)methyl)-7-methoxy-coumarin (8)
This compound was prepared from 4 (0.32, 1.0 mmol) and 6 [20] 
7-Methyl-4-((2-methyl-4-nitro-1H-imidazol-1-yl)methyl)-coumarin (10)
This compound was prepared from 9 (0.13, 1.0 mmol) and 5 (0.25 g, 1.0 mmol), by following the procedure used for the preparation of 7. Yield: 0.21 g. 
7-Methoxy-4-((2-methyl-4-nitro-1H-imidazol-1-yl)methyl)-coumarin (11)
This compound was prepared from 9 (0.13 g, 1.0 mmol) and 6 (0.27 g, 1.0 mmol), using the procedure employed for the preparation of 7. Yield: 0.25 g. 
4-((4-(Benzo[d]oxazol-2-yl)piperazin-1-yl)methyl)-7-methoxy-coumarin (14)
This compound was prepared from 12 [34] (0.20 g, 1.0 mmol) and 6 (0.27 g, 1.0 mmol), by following the same procedure used for the preparation of 7. Yield: 0.26 g. 
1-(4-(Benzo[d]thiazol-2-yl)piperazin-1-yl)-2-chloroethanone (15)
To a solution of 13 [41] (0.22 g, 1.0 mmol) in CH 2 Cl 2 (15 mL) containing Et 3 N (110 mg, 1.0 mmol) was added chloroacetyl chloride (0.11 mg, 1.0 mmol) and the mixture was stirred at 23 • C for 3 h. The solution was evaporated to dryness and the residue was recrystallized from EtOH to give 15. Yield: 0.28 g. 
2-(2-(4-(Benzo[d]thiazol-2-yl)piperazin-1-yl)-2-oxoethyl)-isoindoline-1,3-dione (16)
To a solution of 15 (0.30 g, 1.0 mmol) in DMF (70 mL) was added potassium phthalamide (0.18 g, 1.0 mmol) and the mixture was stirred for 24 h at 120 -130 • C. After cooling, the mixture was evaporated to dryness and the residue was partitioned between dichloromethane (3 × 100 mL) and water (30 mL). The combined organic extracts were dried (Na 2 SO 4 ), filtered, and evaporated to dryness to give 16. Yield: 0.37 g. 
2-Amino-1-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl) ethanone (17)
A solution of 16 (0.81 g, 2.0 mmol) and hydrazine hydrate (2.5 g, 5.0 mmol) in abs. EtOH (15 mL) was heated under reflux for 1.5 h. After cooling in an ice bath, conc. HCl (1.0 mL) was added, the precipitate was filtered, and the filtrate was brought to pH > 10 by the addition of 1 M NaOH solution and extracted with CHCl 3 (3 × 10 mL). The combined organic extracts were dried (Na 2 SO 4 ), filtered and evaporated to dryness to give 17. Yield: 0.45 g. (19) A solution of 17 (0.56 g, 2.0 mmol) and sulphonyl chloride 18 [20] (0.54 g, 2.0 mmol) in CH 2 Cl 2 (50 mL) containing Et 3 N (0.20 mL, 2.0 mmol) was stirred for 16 h, followed by extraction with dilute sodium bicarbonate solution (20 mL). The organic extract was dried (Na 2 SO 4 ), filtered, and evaporated to dryness. The residue was purified on silica gel colums (10 g) using chloroform-methanol (4 : 1) as eluent to give compound 19. Yield: 0.73 g. 
Ethyl 3-((4-(1-benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)-piperazin-1-yl)methyl)-6-methoxy-benzofuran-2-carboxylate (21)
This compound was prepared from 4 (0.32 g, 1.0 mmol) and 20 [42] (0.31 g, 1.0 mmol), by following the procedure used for the preparation of 7. Yield: 0.34 g. 
Ethyl 6-methoxy-3-((2-methyl-4-nitro-1H-imidazol-1-yl)-methyl)benzofuran-2-carboxylate (22)
This compound was prepared from 9 (0.13, 1.0 mmol) and 20 [43] (0.31 g, 1.0 mmol), by following the procedure employed for the preparation of 7. Yield: 0.17 g. 
